Translate bio, inc. (TBIO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Collaboration revenue

10,984

7,804

4,152

0

0

-

0

-

-

-

-

Operating expenses:
Research and development

80,385

76,369

68,513

64,151

62,745

58,024

0

0

0

0

0

General and administrative

29,536

28,632

27,164

26,240

24,381

22,606

0

0

0

0

0

Change in fair value of contingent consideration

-21,141

13

-17,812

28,851

31,814

25,020

0

0

0

0

0

Impairment of intangible asset

-

-

0

-

-

-

-

-

-

-

-

Total operating expenses

107,339

123,573

96,424

119,242

118,940

105,650

0

0

0

0

0

Loss from operations

-96,355

-115,769

-91,328

-115,174

-116,046

-104,230

0

0

0

0

0

Other income (expense):
Interest income, net

1,998

2,010

2,132

2,022

1,755

1,323

0

0

0

0

0

Other expense

-

-

0

-

-

-53

0

0

0

-

0

Total other income (expense), net

-

-

2,110

2,013

-

1,270

0

0

0

0

0

Loss before benefit from income taxes

-94,377

-113,779

-89,218

-113,161

-114,332

-102,960

0

0

0

0

0

Benefit from income taxes

0

-486

-924

-3,448

-4,948

-5,565

0

0

0

0

0

Net loss

-94,377

-113,293

-88,294

-109,713

-109,384

-97,395

0

0

0

0

0

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

644

0

0

0

0

0

Net loss attributable to common stockholders

-

-

-88,294

-109,713

-

-98,039

0

0

0

0

0

Net loss per share—basic and diluted

-0.24

-0.48

-0.41

-0.57

-0.74

2.72

-0.97

-3.04

-2.35

-2.40

-2.31

Weighted average common shares outstanding—basic and diluted

60,008

60,136

51,891

48,749

45,004

45,466

44,036

9,187

9,091

7,781

7,676